Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.

In conclusion, rituximab may be an effective second-line therapy in GO patients, providing long-lasting remission. PMID: 29937466 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research